Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. This is a multicenter, randomized, double-blind prospective study on use of Denosumab versus Alendronate in the therapy of secondary osteoporosis related to ADT.
Treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients. A prospective randomized multicenter international study with Denosumab Vs Alendronate / Doria, Carlo; Mosele, Giulia R; Solla, Federico; Maestretti, Gianluca; Balsano, Massimo; Scarpa, Roberto M.. - In: MINERVA UROLOGICA E NEFROLOGICA. - ISSN 0393-2249. - 69:3(2017), pp. 271-277.
Treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients. A prospective randomized multicenter international study with Denosumab Vs Alendronate
DORIA, Carlo;
2017-01-01
Abstract
Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. This is a multicenter, randomized, double-blind prospective study on use of Denosumab versus Alendronate in the therapy of secondary osteoporosis related to ADT.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
